{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:40:14Z","timestamp":1787614814232,"version":"build-2736575974"},"reference-count":24,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The wide use of ruxolitinib, approved for treating primary and secondary myelofibrosis (MF), has revolutionized the landscape of these diseases. This molecule can reduce spleen volume and constitutional symptoms, guaranteeing patients a better quality of life and survival or even a valid bridge to bone marrow transplantation. Despite a rapid response within the first 3 to 6 months of treatment, some patients fail to achieve a significant benefit or lose early response. After ruxolitinib failure, new drugs are available to provide an additional therapeutic option for these patients. However, the correct timing point for deciding on a therapy shift is still an open challenge. Recently, a clinical prognostic score named RR6 (Response to Ruxolitinib after 6 months) was proposed to determine survival after 6 months of treatment with ruxolitinib in patients affected by MF. We applied this model to a cohort of consecutive patients treated at our center to validate the results obtained in terms of median overall survival (mOS): for the low-risk class, mOS was not reached (as in the training cohort); for the intermediate-risk, mOS was 52 months (95% CI 39\u2013106); for the high-risk, it was 33 (95% 8.5\u201359). Moreover, in addition to the other studies present in the literature, we evaluated how the new RR6 score could better identify primary MF patients at high risk, with a slight or no agreement compared to DIPSS, contrary to what occurs in secondary MF. Thus, we were able to confirm the predictive power of the RR6 model in our series, which might be of help in guiding future therapeutic choices.<\/jats:p>","DOI":"10.3390\/jcm11247418","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T03:01:51Z","timestamp":1671073311000},"page":"7418","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9510-4755","authenticated-orcid":false,"given":"Andrea","family":"Duminuco","sequence":"first","affiliation":[{"name":"Postgraduate School of Hematology, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Nardo","sequence":"additional","affiliation":[{"name":"Postgraduate School of Hematology, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Garibaldi","sequence":"additional","affiliation":[{"name":"Postgraduate School of Hematology, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1922-5157","authenticated-orcid":false,"given":"Calogero","family":"Vetro","sequence":"additional","affiliation":[{"name":"Hematology Unit with BMT, A.O.U. Policlinico \u201cG. Rodolico-San Marco\u201d, Via S. Sofia 78, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Longo","sequence":"additional","affiliation":[{"name":"Hematology Unit with BMT, A.O.U. Policlinico \u201cG. Rodolico-San Marco\u201d, Via S. Sofia 78, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesarina","family":"Giallongo","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Mediche, Chirurgiche e Tecnologie Avanzate \u201cG.F. Ingrassia\u201d, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[{"name":"Hematology Unit with BMT, A.O.U. Policlinico \u201cG. Rodolico-San Marco\u201d, Via S. Sofia 78, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1859-6319","authenticated-orcid":false,"given":"Giuseppe A.","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Mediche, Chirurgiche e Tecnologie Avanzate \u201cG.F. Ingrassia\u201d, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical Effect of Driver Mutations of JAK2, CALR, or MPL in Primary Myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.leukres.2017.06.001","article-title":"Patients with Post-Essential Thrombocythemia and Post-Polycythemia Vera Differ from Patients with Primary Myelofibrosis","volume":"59","author":"Masarova","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and Prognosis in Primary Myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New Prognostic Scoring System for Primary Myelofibrosis Based on a Study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A Dynamic Prognostic Model to Predict Survival in Primary Myelofibrosis: A Study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information from Karyotype, Platelet Count, and Transfusion Status","volume":"29","author":"Gangat","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A Clinical-Molecular Prognostic Model to Predict Survival in Patients with Post Polycythemia Vera and Post Essential Thrombocythemia Myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00277-019-03847-z","article-title":"Tracing the Decision-Making Process for Myelofibrosis: Diagnosis, Stratification, and Management of Ruxolitinib Therapy in Real-Word Practice","volume":"99","author":"Breccia","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/hon.2429","article-title":"Efficacy and Safety of Ruxolitinib in Intermediate-1 IPSS Risk Myelofibrosis Patients: Results from an Independent Study","volume":"36","author":"Palandri","year":"2018","journal-title":"Hematol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1053\/j.seminhematol.2018.05.013","article-title":"Differences in Presenting Features, Outcome and Prognostic Models in Patients with Primary Myelofibrosis and Post-Polycythemia Vera and\/or Post-Essential Thrombocythemia Myelofibrosis Treated with Ruxolitinib. New Perspective of the MYSEC-PM in a Large Multicenter Study","volume":"55","author":"Palandri","year":"2018","journal-title":"Semin. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.16462","article-title":"Primary Analysis of JUMP, a Phase 3b, Expanded-Access Study Evaluating the Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis, Including Those with Low Platelet Counts","volume":"189","author":"Griesshammer","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cncr.32664","article-title":"Life after Ruxolitinib: Reasons for Discontinuation, Impact of Disease Phase, and Outcomes in 218 Patients with Myelofibrosis","volume":"126","author":"Palandri","year":"2020","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/bloodadvances.2021006889","article-title":"A Prognostic Model to Predict Survival after 6 Months of Ruxolitinib in Patients with Myelofibrosis","volume":"6","author":"Maffioli","year":"2022","journal-title":"Blood Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1182\/bloodadvances.2022008158","article-title":"RR6 Prognostic Model Provides Information about Survival for Myelofibrosis Treated with Ruxolitinib: Validation in a Real-Life Cohort","volume":"6","author":"Scalzulli","year":"2022","journal-title":"Blood Adv."},{"key":"ref_18","first-page":"515","article-title":"Concordance Analysis: Part 16 of a Series on Evaluation of Scientific Publications","volume":"108","author":"Kwiecien","year":"2011","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_19","first-page":"28","article-title":"Validity and Reliability of the Research Instrument; How to Test the Validation of a Questionnaire\/Survey in a Research","volume":"5","author":"Lumpur","year":"2016","journal-title":"Int. J. Acad. Res. Manag."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S336","DOI":"10.1016\/S2152-2650(22)01457-4","article-title":"MPN-379 Matching-Adjusted Indirect Comparison (MAIC) of Pelabresib (CPI-0610) in Combination With Ruxolitinib vs. JAK Inhibitor Monotherapy in Patients With Intermediate or High-Risk Myelofibrosis","volume":"22","author":"Gupta","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/S2152-2650(22)00668-1","article-title":"EXABS-164-MPN Novel Therapeutics in Development for Myelofibrosis","volume":"22","author":"Chifotides","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S340","DOI":"10.1016\/S2152-2650(22)01464-1","article-title":"MPN-483 Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM]","volume":"2","author":"Gerds","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/bjh.17850","article-title":"The Immune Landscape in BCR-ABL Negative Myeloproliferative Neoplasms: Inflammation, Infections and Opportunities for Immunotherapy","volume":"196","author":"Strickland","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s12185-022-03335-7","article-title":"Role of JAK Inhibitors in Myeloproliferative Neoplasms: Current Point of View and Perspectives","volume":"115","author":"Loscocco","year":"2022","journal-title":"Int. J. Hematol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/24\/7418\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:41:19Z","timestamp":1760146879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/24\/7418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":24,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["jcm11247418"],"URL":"https:\/\/doi.org\/10.3390\/jcm11247418","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,14]]}}}